Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong

References

• World Health Organization. Pneumococcal disease; 2011 [accessed 2015 Nov 27]. http://www.who.int/immunization/topics/pneumococcal_disease/en/.
   Google Scholar
• Centre for Health Protection, Department of Health, The Government of Hong Kong Special Administrative Region. Scientific committee on vaccine preventable diseases updated recommendations on the use of pneumococcal vaccines for high-risk individuals; 2016 [accessed 2017 Jun 2]. http://www.chp.gov.hk/en/sas6/101/110/106.html.
   Google Scholar
• Bravo LC. Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009;27(52):7282–91. doi:10.1016/j.vaccine.2009.04.046.
   PubMed Web of Science ®Google Scholar
• Domínguez À, Soldevila N, Toledo D, Torner N, Force L, Pérez MJ, Martín V, Rodríguez-Rojas L, Astray J, Egurrola M, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain. PLoS One 2017;12(2):e0171943–e0171943. doi:10.1371/journal.pone.0171943.
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Schraufnagel DE. Pneumococcal vaccines: understanding centers for disease control and prevention recommendations. Ann Am Thorac Soc. 2014;11(6):980–85. doi:10.1513/AnnalsATS.201401-042CME.
   PubMedGoogle Scholar
• Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in adults. Drugs 2015;75(13):1535–46. doi:10.1007/s40265-015-0449-z.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal disease: vaccine; 2017 [accessed 2017 Jan 19]. http://www.who.int/ith/vaccines/pneumococcal/en/.
   Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AMM, Sanders EAM, Verheij TJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544.
   PubMed Web of Science ®Google Scholar
• Stockmann C, Byington CL. PCV13 in the USA: early successes and potential challenges. Lancet Infect Dis. 2015;15(3):254–56. doi:10.1016/S1473-3099(15)70018-6.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Am J Prev Med. 2015;49(6 Suppl 4):S383–390. doi:10.1016/j.amepre.2015.09.008.
   PubMed Web of Science ®Google Scholar
• The Advisory Committee on Immunization Practices. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP); 2012 [accessed 2015 Nov 4]. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm#tab.
   Google Scholar
• National Advisory Committee on Immunization, Public Health Agency of Canada. Statement on the use of conjugate pneumococcal vaccine - 13 valent in adults (Pneu-C-13); 2013 [accessed 2017 Jun 7]. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-5/index-eng.php#rec.
   Google Scholar
• Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014;31(10):1011–44. doi:10.1007/s12325-014-0157-1.
   PubMed Web of Science ®Google Scholar
• Atwood M, Beausoleil L, Breton M-C, Laferriere C, Sato R, Weycker D. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. Can J Public Health 2018;109(5–6):756–68. doi:10.17269/s41997-018-0050-9.
   PubMed Web of Science ®Google Scholar
• Chen J, O’Brien MA, Yang HK, Grabenstein JD, Dasbach EJ. Cost-effectiveness of pneumococcal vaccines for adults in the United States. Adv Ther. 2014;31(4):392–409. doi:10.1007/s12325-014-0115-y.
   PubMed Web of Science ®Google Scholar
• Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, Kim WJ, Kim MJ, Lee HY, Song JY, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One 2017;12(5):e0177342. doi:10.1371/journal.pone.0177342.
   PubMed Web of Science ®Google Scholar
• Hospital Authority of Hong Kong. Hospital authority. Drug formulary management manual (Version 0.6); 2015 [accessed 2017 Jan 24]. http://www.ha.org.hk/haho/ho/cad_bnc/AOM-P1108.pdf.
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316(10):1093–103. doi:10.1001/jama.2016.12195.
   PubMed Web of Science ®Google Scholar
• Li X, Blais JE, Wong ICK, Tam AWY, Cowling BJ, Hung IFN, Chan EWY. Population-based estimates of the burden of pneumonia hospitalizations in Hong Kong, 2011–2015. Eur J Clin Microbiol Infect Dis. 2019;38(3):553–61. doi:10.1007/s10096-018-03459-x.
   PubMed Web of Science ®Google Scholar
• Center for Health Protection, Department of Health, The Government of HKSAR. Report on IPD in 2017; 2015 [accessed 2018 Nov 25]. https://www.chp.gov.hk/en/resources/29/100015.html.
   Google Scholar
• Örtqvist Å, Hedlund J, Burman L-Å, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelöf B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351(9100):399–403. doi:10.1016/S0140-6736(97)07358-3.
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60. doi:10.1056/NEJM199111213252101.
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, Wittrup-Jensen K, Loiseau C, Fedson DS. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531–40. doi:10.1007/s10096-007-0327-z.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko F-S, McEllistrem MC, Roberts MS. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008;26(11):1420–31. doi:10.1016/j.vaccine.2008.01.007.
   PubMed Web of Science ®Google Scholar
• Mufson MA, Krause HE, Schiffman G, Hughey DF. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci. 1987;293(5):279–84. doi:10.1097/00000441-198705000-00001.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Barradas MC, Musher DM, Lahart C, Lacke C, Groover J, Watson D, Baughn R, Cate T, Crofoot G. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis. 1992;165(3):553–56. doi:10.1093/infdis/165.3.553.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012;307(8):804–12. doi:10.1001/jama.2012.169.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med. 2013;44(4):373–81. doi:10.1016/j.amepre.2012.11.035.
   PubMed Web of Science ®Google Scholar
• Liguori G, Parlato A, Zamparelli AS, Parlato A, Zamparelli AS, Zamparelli AS, Belfiore P, Belfiore P, Gallé F, Gallé F, et al. Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy an economic evaluation. Hum Vaccin Immunother. 2014;10(2):492–97. doi:10.4161/hv.26888.
   PubMed Web of Science ®Google Scholar
• Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, van Deursen AMM, van der Ende A, Grobbee DE, Sanders EAM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–16. doi:10.1183/13993003.00325-2015.
   PubMed Web of Science ®Google Scholar
• Rodriguez Gonzalez-Moro JM, Menendez R, Campins M, Lwoff, N., Oyagüez, I., Echave, M., Rejas, J., Antonanzas, F. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain. Clin Drug Investig.
   Web of Science ®Google Scholar
• Centre for Health Protection, Department of Health, HKSAR. Number of deaths by leading causes of death by sex by age in 2017; 2018 [accessed 2019 Jan 7]. https://www.chp.gov.hk/en/statistics/data/10/27/340.html.
   Google Scholar
• Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–27. doi:10.1056/NEJMoa1500245.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018;67(10):1498–506. doi:10.1093/cid/ciy312.
   PubMed Web of Science ®Google Scholar